Cidara Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference
Cidara Therapeutics (Nasdaq: CDTX), a biotechnology company leveraging its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, has announced its participation in the upcoming Guggenheim Securities SMID Cap Biotech Conference.
The company's President and CEO, Jeffrey Stein, Ph.D., will engage in a fireside chat on Wednesday, February 5, 2025, at 1:30 PM ET. The presentation will be available via webcast and can be accessed through a provided link. A replay will be accessible in the Investors section of Cidara's website for 90 days following the event.
Additionally, Cidara will conduct one-on-one investor meetings during the conference. Interested investors should contact their Guggenheim representative to arrange meetings.
Cidara Therapeutics (Nasdaq: CDTX), una società biotecnologica che sfrutta la propria piattaforma Cloudbreak® per sviluppare immunoterapie a base di coniugati di farmaci-Fc (DFC), ha annunciato la propria partecipazione alla prossima Guggenheim Securities SMID Cap Biotech Conference.
Il presidente e CEO dell'azienda, Jeffrey Stein, Ph.D., parteciperà a una chat informale mercoledì 5 febbraio 2025, alle 13:30 ET. La presentazione sarà disponibile tramite webcast e sarà accessibile tramite un link fornito. Una registrazione sarà disponibile nella sezione Investitori del sito web di Cidara per 90 giorni dopo l'evento.
Inoltre, Cidara condurrà incontri individuali con gli investitori durante la conferenza. Gli investitori interessati dovrebbero contattare il proprio rappresentante di Guggenheim per organizzare gli incontri.
Cidara Therapeutics (Nasdaq: CDTX), una compañía de biotecnología que utiliza su plataforma Cloudbreak® para desarrollar inmunoterapias de conjugados de fármacos-Fc (DFC), ha anunciado su participación en la próxima Guggenheim Securities SMID Cap Biotech Conference.
El presidente y CEO de la compañía, Jeffrey Stein, Ph.D., participará en un chat informal el miércoles 5 de febrero de 2025, a la 1:30 PM ET. La presentación estará disponible a través de un webcast y se podrá acceder a través de un enlace proporcionado. Una grabación estará disponible en la sección de Inversores del sitio web de Cidara durante 90 días tras el evento.
Además, Cidara llevará a cabo reuniones individuales con inversores durante la conferencia. Los inversores interesados deben contactar a su representante de Guggenheim para organizar las reuniones.
시다라 테라퓨틱스 (Nasdaq: CDTX), 클라우드브레이크(Cloudbreak®) 플랫폼을 활용하여 약물-Fc 접합체(DFC) 면역 치료제를 개발하는 생명공학 회사가 다가오는 구겐하임 증권 SMID 캡 생명공학 회의에 참여한다고 발표했습니다.
회사의 회장兼 CEO인 제프리 스타인 박사(Dr. Jeffrey Stein)는 2025년 2월 5일 수요일, 오후 1시 30분 ET에 대화 세션에 참석할 예정입니다. 프레젠테이션은 웹캐스트를 통해 제공되며, 제공된 링크를 통해 접근할 수 있습니다. 행사가 끝난 후 90일 동안 시다라 웹사이트의 투자자 섹션에서 재생할 수 있습니다.
추가로, 시다라는 회의 중 개별 투자자 미팅을 진행합니다. 관심 있는 투자자는 구겐하임 담당자에게 연락하여 미팅을 조율해야 합니다.
Cidara Therapeutics (Nasdaq: CDTX), une entreprise de biotechnologie utilisant sa plateforme Cloudbreak® pour développer des immunothérapies par conjugés de médicaments-Fc (DFC), a annoncé sa participation à la prochaine Guggenheim Securities SMID Cap Biotech Conference.
Le président et CEO de l'entreprise, Jeffrey Stein, Ph.D., participera à une discussion informelle le mercredi 5 février 2025, à 13h30 ET. La présentation sera disponible par webcast et pourra être consultée via un lien fourni. Un enregistrement sera accessible dans la section Investisseurs du site web de Cidara pendant 90 jours après l'événement.
De plus, Cidara réalisera des réunions individuelles avec les investisseurs durant la conférence. Les investisseurs intéressés doivent contacter leur représentant Guggenheim pour organiser ces réunions.
Cidara Therapeutics (Nasdaq: CDTX), ein Biotechnologieunternehmen, das seine eigene Cloudbreak®-Plattform nutzt, um Arzneimittel-Fc-Konjugate (DFC) Immuntherapien zu entwickeln, hat seine Teilnahme an der bevorstehenden Guggenheim Securities SMID Cap Biotech Conference angekündigt.
Der Präsident und CEO des Unternehmens, Jeffrey Stein, Ph.D., wird am Mittwoch, den 5. Februar 2025, um 13:30 Uhr ET an einem informellen Gespräch teilnehmen. Die Präsentation wird über einen Webcast verfügbar sein und kann über einen bereitgestellten Link aufgerufen werden. Eine Aufzeichnung wird für 90 Tage nach der Veranstaltung im Investorenbereich der Cidara-Website verfügbar sein.
Darüber hinaus wird Cidara während der Konferenz Einzelgespräche mit Investoren führen. Interessierte Investoren sollten ihren Guggenheim-Vertreter kontaktieren, um Meetings zu vereinbaren.
- None.
- None.
SAN DIEGO, Jan. 30, 2025 (GLOBE NEWSWIRE) -- Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies designed to save lives and improve the standard of care for patients facing serious diseases, today announced that Jeffrey Stein, Ph.D., President and Chief Executive Officer, will participate in the Guggenheim Securities SMID Cap Biotech Conference.
Details are as follows:
Event: Guggenheim Securities SMID Cap Biotech Conference
Date: Wednesday, February 5, 2025
Time: 1:30 PM ET
Format: Fireside chat
Webcast: https://wsw.com/webcast/guggen2/cdtx/2014749
A replay of the presentation will be available in the Investors section on the Company’s website at www.cidara.com. The replay of the presentation will be available for 90 days.
Cidara will also participate in one-on-one investor meetings during this event. Investors interested in meeting with Cidara at the conference should contact their Guggenheim representative directly.
About Cidara Therapeutics
Cidara Therapeutics is using its proprietary Cloudbreak® platform to develop novel drug-Fc conjugates (DFCs) comprising targeted small molecules or peptides coupled to a proprietary human antibody fragment (Fc). Cidara’s lead DFC candidate, CD388, is a long-acting antiviral designed to achieve universal prevention of seasonal and pandemic influenza with a single dose by directly inhibiting viral proliferation. In June 2023, CD388 was granted Fast Track Designation by the U.S. Food and Drug Administration (FDA), and the Company announced completion of Phase 2b enrollment in December 2024. Additional DFCs have been developed for oncology and in July 2024 Cidara received IND clearance for CBO421 which is intended to target CD73 in solid tumors. Cidara is headquartered in San Diego, California. For more information, please visit www.cidara.com.
INVESTOR CONTACT:
Brian Ritchie
LifeSci Advisors
(212) 915-2578
britchie@lifesciadvisors.com
MEDIA CONTACT:
Michael Fitzhugh
LifeSci Communications
mfitzhugh@lifescicomms.com
FAQ
When is Cidara Therapeutics (CDTX) presenting at the Guggenheim SMID Cap Biotech Conference 2025?
How can investors access CDTX's Guggenheim Conference presentation webcast?
How long will CDTX's Guggenheim Conference presentation replay be available?
What type of presentation format will CDTX deliver at the Guggenheim Biotech Conference?
How can investors arrange one-on-one meetings with CDTX at the Guggenheim Conference?
